Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Bayer
Thumbnail
August 08, 2022

US drug pricing reform happens at last

As a host of industry-hated proposals look like becoming law in the US, Evaluate Vantage explains what might be coming.

Thumbnail
August 03, 2022

Rigel makes Forma wait for olutasidenib payday

Article image
Vantage logo
August 02, 2022

Perkinelmer sells rather than spins

Article image
Vantage logo
July 29, 2022

No place for Wee1 in Astra’s synthetic lethality work

Wee1 competitors including Zentalis might look with trepidation on Astra and Roche’s recent moves into ATR inhibition.

Article image
Vantage logo
July 21, 2022

Vertex gets more in vivo gene editing Verve

Article image
Vantage logo
July 13, 2022

Few biopharma risers stand out at the half year

A look for winners and losers finds a sector laid low by poor sentiment and Covid fatigue, with Lantheus, Vertex and Jazz providing a few bright spots.

Article image
Vantage logo
July 13, 2022

Orion’s cancer reset bears fruit

Already boasting the marketed Nubeqa, Orion licenses its next-biggest prostate cancer hope to Merck & Co.

Article image
Vantage logo
June 29, 2022

Biotech’s important data reveals

Key upcoming clinical results approach in the third quarter for lecanemab, high-dose Eylea and Zimura.

Article image
Vantage logo
June 14, 2022

Roche deal fails to Repare the licensing scene

Few sizeable transactions have emerged so far this year, with small licensing deals looking like the norm.

Article image
Vantage logo
June 07, 2022

Asco 2022 – looking beyond Enhertu in Her2-low cancer

Article image
Vantage logo
June 03, 2022

Turning Point and Libtayo steal some pre-Asco thunder

On the eve of Asco two deals show that the current biotech market malaise might be focusing some chief executives’ minds.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

August 15, 2022

Q2 Roundp Medtech Infographic

August 12, 2022

Q2 Roundup Pharma Infographic

View more...

Editor's Picks

Vantage logo
July 27, 2022

Aids 2022 preview – Gilead shoots for an HIV cure

Vantage logo
July 21, 2022

Private equity gets serious about drug development

Vantage logo
July 18, 2022

Unpacking Royalty Pharma

Vantage logo
July 19, 2022

No plain sailing for Novartis’s PD-1 plan

Vantage logo
July 26, 2022

Move over Aduhelm, it’s tofersen’s turn

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.